Search results for "Adrenergic"

showing 10 items of 433 documents

Effects of omalizumab in severe asthmatics across ages: A real life Italian experience

2016

Background This retrospective study aimed at evaluating long-term effects of Omalizumab in elderly asthmatics in a real-life setting. Methods 105 consecutive severe asthmatics (GINA step 4–5; mean FEV1% predicted:66 ± 15.7) treated with Omalizumab for at least 1 year (treatment mean duration 35.1 ± 21.7 months) were divided into 3 groups according to their age at Omalizumab treatment onset: 18–39, 40–64 and ≥ 65 years. Results Comorbidities, number of overweight/obese subjects and patients with late-onset asthma were more frequent among older people. A similar reduction of inhaled corticosteroids dosage and SABA on-demand therapy was observed in all groups during Omalizumab treatment; a sim…

MaleSevere asthmaPediatricsComorbidityOmalizumabOmalizumabOverweightImmunoglobulin ESeverity of Illness IndexElderly0302 clinical medicineAdrenal Cortex HormonesForced Expiratory VolumeAge effectAnti-Asthmatic Agentsasthma allergy elderly omalizumab030212 general & internal medicineYoung adultbiologyReal-lifeAdrenergic beta-AgonistsMiddle AgedTreatment OutcomeItalyFemalemedicine.symptommedicine.drugAdultPulmonary and Respiratory Medicineage effect; elderly; omalizumab; real-life; severe asthmamedicine.medical_specialtyAdolescentSettore MED/10 - Malattie Dell'Apparato RespiratorioAntibodies Monoclonal HumanizedYoung Adult03 medical and health sciencesAge effect; Elderly; Omalizumab; Real-life; Severe asthma; Pulmonary and Respiratory MedicineAdministration InhalationSeverity of illnessmedicineHumansAgedRetrospective StudiesAsthmabusiness.industryRetrospective cohort studyImmunoglobulin Easthmaallergymedicine.diseaseComorbidity030228 respiratory systembiology.proteinbusinessRespiratory Medicine
researchProduct

The new radioligand [H-3]-L 748,337 differentially labels human and rat beta(3)-adrenoceptors

2013

As no suitable radioligand exists for the detection of β3-adrenoceptors, we have explored the radioligand binding properties of a tritiated version of the selective β3-adrenoceptor antagonist L 748,337. Kinetic and equilibrium saturation and competition binding experiments were performed with [(3)H]-L 748,337 on membrane fractions of HEK and CHO cells stably transfected with human and rat β-adrenoceptor subtypes. Based on both association/dissociation kinetic and equilibrium saturation binding studies in transfected HEK cells, [(3)H]-L 748,337 exhibited an affinity of approximately 2 nM for human β3-adrenoceptors. Competition studies with agonists and subtype-selective antagonists validated…

MaleStereochemistryUrinary BladderCHO CellsIn Vitro TechniquesAminophenolsBinding CompetitiveRats Sprague-Dawley03 medical and health sciencesRadioligand Assay0302 clinical medicineCricetulusRadioligandAnimalsHumans030304 developmental biologyPharmacology0303 health sciencesSulfonamidesbiologyChemistryChinese hamster ovary cellHEK 293 cellsAntagonistMuscle SmoothTransfectionbiology.organism_classificationMolecular biologyRadioligand AssayRatsMembraneHEK293 CellsReceptors Adrenergic beta-3CricetulusAdrenergic beta-3 Receptor Antagonists030217 neurology & neurosurgeryEuropean Journal of Pharmacology
researchProduct

Pharmacologic pupil dilation as a predictive test for the risk for intraoperative floppy-iris syndrome.

2011

PURPOSE: To evaluate the effect of α1-adrenergic receptor antagonists (α1-ARAs) on pupil diameter and determine whether the diameter predicts intraoperative floppy-iris syndrome (IFIS). SETTING: Ophthalmology Section, Palermo University, Palermo, Italy. DESIGN: Prospective cohort study. METHODS: Male outpatients taking tamsulosin, α(1)-ARAs, or no α(1)-ARAs having phacoemulsification were recruited. Pupils were measured 1 month preoperatively, immediately preoperatively, and postoperatively under mesopic low (0.4 lux) and high (4.0 lux) illumination after pharmacologic dilation. The IFIS severity was graded. RESULTS: Each group comprised 50 patients. Pharmacologic dilation in both α(1)-ARA …

MaleTamsulosinmedicine.medical_specialtyMydriaticsmedicine.medical_treatmentIntraoperative floppy iris syndromeSensitivity and SpecificityPupilCohort StudiesPhenylephrineTropicamideTamsulosinPredictive Value of TestsRisk FactorsmedicinePupillary responseHumansProspective StudiesProspective cohort studyIntraoperative ComplicationsAgedSulfonamidesPhacoemulsificationbusiness.industrySettore MED/30 - Malattie Apparato VisivoDoxazosinfood and beveragesMuscle SmoothPupilPhacoemulsificationPrazosinSyndromebiochemical phenomena metabolism and nutritionmedicine.diseaseSensory SystemsSurgerycarbohydrates (lipids)OphthalmologyDrug CombinationsIfis pupil dilation tamsulosinIris DiseasesPredictive value of testsAdrenergic alpha-1 Receptor AntagonistsSurgerybusinessCohort studymedicine.drugJournal of cataract and refractive surgery
researchProduct

Cognitive and mood side effects of lower urinary tract medication

2019

Introduction: Muscarinic receptor antagonists, 5α-reductase inhibitors and α1-adrenoceptor antagonists are frequently used drug classes for the treatment of lower urinary tract symptoms including those of overactive bladder syndrome and benign prostatic enlargement/benign prostatic obstruction. Areas covered: The authors review the evidence for adverse effects of these drug classes on cognitive function, mood and other functions of the central nervous system and discuss such effects against the evidence for mechanistic plausibility. Expert opinion: Muscarinic antagonists carry a risk for impaired cognition and other brain functions that differs quantitatively between compounds, being highes…

MaleTamsulosinmedicine.medical_specialtyUrinary systemProstatic HyperplasiaMuscarinic Antagonists030204 cardiovascular system & hematology03 medical and health sciences5-alpha Reductase InhibitorsCognition0302 clinical medicineLower Urinary Tract SymptomsLower urinary tract symptomsTamsulosinInternal medicinemedicineAnimalsHumansDementiaPharmacology (medical)OxybutyninAdverse effectDose-Response Relationship DrugUrinary Bladder Overactivebusiness.industryGeneral Medicinemedicine.diseaseDiscontinuationAffectMood030220 oncology & carcinogenesisAdrenergic alpha-1 Receptor Antagonistsbusinessmedicine.drugExpert Opinion on Drug Safety
researchProduct

Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease

2017

Background and purpose While the efficacy and safety of combined tiotropium and olodaterol in patients with COPD was established in a large clinical trial program, it is important to assess whether clinical data can be applied to geographic patient groups, particularly for East Asian patients who may have a different phenotypic profile to the global trial population. This study aimed to compare the lung function and safety profiles of tiotropium/olodaterol and monocomponents in East Asian and global populations from the TONADO® trials. Materials and methods In the replicate, double-blind, parallel-group, active-controlled, randomized, 52-week, Phase III TONADO studies, patients received tio…

MaleTime FactorsHealth StatusVital CapacityCholinergic AntagonistsPulmonary function testingPulmonary Disease Chronic Obstructivechemistry.chemical_compound0302 clinical medicineForced Expiratory Volume030212 general & internal medicineLungLung functionOriginal ResearchCOPDeducation.field_of_studypulmonary functionOlodaterolArea under the curveGeneral MedicineMiddle AgedhumanitiesBronchodilator AgentsDrug CombinationsTreatment OutcomeArea Under CurveFemaleChinamedicine.medical_specialtyPopulationInternational Journal of Chronic Obstructive Pulmonary Disease03 medical and health sciencesAsian PeopleDouble-Blind MethodInternal medicinemedicineHumansCOPDTiotropium BromideAdverse effecteducationAdrenergic beta-2 Receptor AgonistsAgedbusiness.industryRecovery of Functionmedicine.diseaseBenzoxazinesrespiratory tract diseasesClinical trial030228 respiratory systemchemistryQuality of Lifeadverse effectsTONADO®businesshuman activitiesInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study.

2016

OBJECTIVE To assess the association between early and prolonged beta blocker treatment and mortality after acute myocardial infarction. DESIGN Multicentre prospective cohort study. SETTING Nationwide French registry of Acute ST- and non-STelevation Myocardial Infarction (FAST-MI) (at 223 centres) at the end of 2005. PARTICIPANTS 2679 consecutive patients with acute myocardial infarction and without heart failure or left ventricular dysfunction. MAIN OUTCOME MEASURES Mortality was assessed at 30 days in relation to early use of beta blockers (<= 48 hours of admission), at one year in relation to discharge prescription, and at five years in relation to one year use. RESULTS beta blockers were…

MaleTime FactorsMyocardial Infarction030204 cardiovascular system & hematologyCorrectionsCohort Studies0302 clinical medicineMedicine030212 general & internal medicineMyocardial infarctionProspective StudiesProspective cohort studyHazard ratioGeneral MedicineMiddle AgedMetaanalysisPatient Discharge3. Good healthManagementImpactAcute DiseaseCardiologyFemaleLife Sciences & Biomedicinemedicine.medical_specialtyRegistrySt-Segment-Elevationmedicine.drug_classAdrenergic beta-AntagonistsGuidelines03 medical and health sciencesMedicine General & InternalFast-MiInternal medicineGeneral & Internal Medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyClinical-OutcomesHumansBeta blockerSurvival analysisAgedProportional Hazards ModelsHeart FailureScience & Technologybusiness.industryProportional hazards modelResearchCoronary Care Unitsmedicine.diseaseSurvival AnalysisDiscontinuationLogistic ModelsAdherenceHeart failureTherapybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyBMJ (Clinical research ed.)
researchProduct

Effects of beta-adrenoceptor drug stimulation on various models of gastric ulcer in rats.

1982

Abstract 1. Experiments were designed to evaluate the effect of the pharmacological activation of beta-adrenoceptors on various models of gastric ulcer in the rat. 2. Pretreatment with the beta-adrenoceptor stimulant drugs, isoprenaline or salbutamol, significantly inhibited stress-induced gastric ulcers. This anti-ulcer effect was abolished by propranolol but not by atenolol, suggesting that beta 2-adrenoceptors mediate this response. 3. In the pylorus-ligation model, salbutamol inhibited lesion formation and reduced the intragastric content of hydrogen ions, histamine and pepsin although the latter was only affected with the higher dose of salbutamol. 4. Salbutamol also prevented the ulce…

MaleTime FactorsStimulationPropranololPharmacologychemistry.chemical_compoundIsoprenalinemedicineGastric mucosaAnimalsHumansAlbuterolStomach UlcerPylorusPharmacologybusiness.industryIsoproterenolRats Inbred StrainsReserpineAdrenergic beta-AgonistsAtenololdigestive system diseasesRatsmedicine.anatomical_structurechemistryGastric MucosaAnesthesiaSalbutamolbusinessHistamineStress Psychologicalmedicine.drugResearch ArticleBritish journal of pharmacology
researchProduct

Role of central oxytocin in the inhibition by endotoxin of distension-stimulated gastric acid secretion

2000

The gastric acid hyposecretory state associated with endotoxemia is mediated by a nervous reflex involving the central nervous system. The aim of the present study was to analyse the central effects of different peptides on distension-stimulated gastric acid secretion and the endogenous role of such peptides on the hyposecretory effects of endotoxin. The effect of an intracisternal (i.c.) administration of oxytocin, vasopressin, corticotropin releasing factor (CRF), bombesin, somatostatin and the opioid receptor agonist BW443C or an intravenous (i.v.) injection of a small dose of endotoxin on distension-stimulated gastric acid secretion was studied in the continuously perfused stomach of an…

MaleVasopressinendotoxinCorticotropin-Releasing HormonevasopressinNarcotic AntagonistsGastric DilatationOxytocinchemistry.chemical_compoundVasoconstrictor AgentsReceptorChemistryStomachBombesincorticotropin-releasing factorGeneral MedicineSomatostatinmedicine.anatomical_structurebombesinReceptors Oxytocingastric acid secretionBombesinFemaleSomatostatingastric distensionOligopeptidesAntidiuretic Hormone Receptor Antagonistshormones hormone substitutes and hormone antagonistsmedicine.drugmedicine.medical_specialtyVasopressinsReceptors Corticotropin-Releasing HormoneGastric AcidAdrenergic AgentsInternal medicineoxytocinmedicineAnimalsRats WistarInjections IntraventricularPharmacologyDose-Response Relationship Drugcentral nervous systemOxytocin receptorEndotoxemiaHormonesRatsEndotoxinsReceptors BombesinEndocrinologyOxytocinGastric MucosaGastric acid
researchProduct

Effect of nebulized beclomethasone on airway inflammation and clinical status of children with allergic asthma and rhinitis: a randomized, double-bli…

2012

We aimed to evaluate the therapeutic effect of nebulized beclomethasone dipropionate (nBDP) on both allergic asthma and rhinitis. In a randomized, double-blind, placebo-controlled study, 40 children (mean age 10.7 ± 2.1 years) with allergic asthma and rhinitis received either nBDP (daily dose of 800 µg, administered twice daily) or placebo for 4 weeks (with a face mask), after a 2-week run-in period of clinical assessment. Nasal and oral fractional exhaled nitric oxide (FeNO) measurements together with pulmonary function tests, nasal and oral exhaled breath condensate (EBC) collection for pH and interleukin-5 (IL-5) measurements as well as nasal and bronchial symptom scores were obtained at…

MaleVital capacityRhinitis Allergic PerennialAdolescentVisual analogue scaleImmunologyPlacebo-controlled studyPilot ProjectsPlaceboNitric OxidePulmonary function testingDouble-Blind MethodAdministration InhalationmedicineImmunology and AllergyHumansExhaled breath condensateAnti-Asthmatic AgentsChildAdrenergic beta-2 Receptor Agonistsrhinorrheabusiness.industryNebulizers and VaporizersBeclomethasoneGeneral MedicineImmunoglobulin EAsthmarespiratory tract diseasesRespiratory Function TestsBreath TestsAnesthesiaImmunologyExhaled nitric oxideFemalemedicine.symptomInterleukin-5businessbeclomethasone and asthma
researchProduct

A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management--a systematic review and meta-analysis

2012

Abstract Context Nocturia is a common urologic symptom that has been covered in a variety of reported studies in the literature but is not specifically covered in current guidelines. Objective To comprehensively review the literature pertaining to the definition, etiologies, and consequences of nocturia and assess the evidence supporting the use of conservative medical and interventional therapy. Evidence acquisition A literature search was conducted using the keyword nocturia , restricted to articles in the English language, after 2000 and before April 2012, in PubMed/Medline, Embase, Scopus, Web of Science, and Cochrane Library databases. Regarding treatment modalities, studies were inclu…

MaledesmopressinPathologyAnti-Inflammatory AgentsCochrane Libraryurologic and male genital diseaseslaw.inventionsystematic reviewRandomized controlled trialRisk FactorslawEpidemiologyOdds RatioPrevalencea1-blockersDesmopressina1-blockers; alpha(1)-blockers; antimuscarinics; desmopressin; meta-analysis; nocturia; nocturnal polyuria; systematic review; α1-blockersEvidence-Based MedicineAntidiuretic AgentsDiagnostic Techniques UrologicalMiddle AgedPathophysiologyfemale genital diseases and pregnancy complicationsTreatment OutcomeMeta-analysisUrologic Surgical ProceduresFemaleNocturiaα1-blockersmedicine.symptommedicine.drugmedicine.medical_specialtyUrologyMEDLINEMuscarinic Antagonistsalpha(1)-blockersPredictive Value of TestsInternal medicinemedicineHumansNocturiaIntensive care medicineantimuscarinicsAgedChi-Square Distributionbusiness.industrynocturnal polyuriaEvidence-based medicinemeta-analysisClinical trialUrodynamicsEndocrinologyAdrenergic alpha-1 Receptor AntagonistsbusinessEuropean urology
researchProduct